US Stock MarketDetailed Quotes
RXRX Recursion Pharmaceuticals
- 6.930
- -0.040-0.57%
Close Nov 7 16:00 ET
- 6.990
- +0.060+0.87%
Post 20:01 ET
1.99BMarket Cap-4500P/E (TTM)
7.090High6.680Low5.80MVolume6.920Open6.970Pre Close40.19MTurnover2.26%Turnover RatioLossP/E (Static)286.64MShares15.74052wk High3.79P/B1.78BFloat Cap5.21552wk Low--Dividend TTM257.07MShs Float42.810Historical High--Div YieldTTM5.88%Amplitude4.540Historical Low6.929Avg Price1Lot Size
Recursion Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 158.19%26.08M | 30.76%14.4M | 11.18%13.49M | 10.57%43.88M | -22.32%10.62M | -22.61%10.1M | 43.94%11.02M | 128.99%12.13M | 296.81%39.68M | 447.04%13.68M |
| Operating revenue | 158.19%26.08M | 30.76%14.4M | 11.18%13.49M | 10.57%43.88M | -22.32%10.62M | -22.61%10.1M | 43.94%11.02M | 128.99%12.13M | 296.81%39.68M | 447.04%13.68M |
| Cost of revenue | 11.05%12.08M | -1.95%9.2M | -10.30%11.17M | -11.78%42.59M | -8.85%9.88M | -29.41%10.88M | -34.05%9.38M | 59.61%12.45M | 48.28M | 10.84M |
| Gross profit | 1,906.84%14M | 218.54%5.21M | 840.45%2.33M | 115.00%1.29M | -73.80%743K | 67.11%-775K | 124.86%1.63M | 87.44%-314K | -185.94%-8.59M | 13.44%2.84M |
| Operating expense | 13.75%112.36M | 26.87%105.75M | 41.86%98.67M | 48.17%351.35M | 56.18%99.67M | 64.03%98.78M | 39.81%83.35M | 30.05%69.55M | 23.01%237.13M | -5.40%63.82M |
| Selling and administrative expenses | 29.31%37.76M | 12.52%31.83M | 37.31%31.41M | 35.81%110.82M | 53.53%30.46M | 49.83%29.2M | 33.45%28.29M | 8.54%22.87M | 41.46%81.6M | 3.32%19.84M |
| -General and administrative expense | 29.31%37.76M | 12.52%31.83M | 37.31%31.41M | 35.81%110.82M | 53.53%30.46M | 49.83%29.2M | 33.45%28.29M | 8.54%22.87M | 41.46%81.6M | 3.32%19.84M |
| Research and development costs | 6.56%74.6M | 34.27%73.93M | 44.74%67.56M | 54.93%241.23M | 57.99%69.48M | 71.43%70.01M | 43.24%55.06M | 43.88%46.68M | 15.10%155.7M | -8.93%43.98M |
| Other operating expenses | ---- | -1,200.00%-13K | ---303K | -331.48%-699K | ---267K | -302.80%-431K | 95.24%-1K | ---- | 8.99%-162K | --0 |
| Operating profit | 1.20%-98.35M | -23.04%-100.54M | -37.89%-96.34M | -42.46%-350.06M | -62.23%-98.93M | -59.09%-99.55M | -23.45%-81.72M | -24.80%-69.87M | -34.44%-245.73M | 6.12%-60.98M |
| Net non-operating interest income expense | -33.91%3.27M | -41.76%2.87M | -13.21%4.03M | 206.81%19.02M | 22.54%4.5M | 172.09%4.95M | 672.88%4.93M | 6,257.53%4.64M | 315.32%6.2M | 183,550.00%3.67M |
| Non-operating interest income | -23.13%3.83M | -34.11%3.27M | -13.13%4.05M | 205.66%19.12M | 22.81%4.52M | 171.52%4.98M | 660.28%4.96M | 5,256.32%4.66M | 8,467.12%6.25M | 17,633.33%3.68M |
| Non-operating interest expense | 2,112.00%553K | 1,415.38%394K | 5.26%20K | 76.36%97K | 100.00%26K | 92.31%25K | 85.71%26K | 35.71%19K | -98.14%55K | 168.42%13K |
| Other net income (expense) | -137.57%-594K | -787.72%-392K | 255.34%160K | -2,190.38%-1.09M | -1,365.92%-2.62M | 413.31%1.58M | 914.29%57K | -45.07%-103K | 106.30%52K | -717.24%-179K |
| Special income (charges) | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| Other non- operating income (expenses) | -137.57%-594K | -787.72%-392K | 255.34%160K | -2,190.38%-1.09M | -1,365.92%-2.62M | 413.31%1.58M | 914.29%57K | -45.07%-103K | 2,500.00%52K | -717.24%-179K |
| Income before tax | -2.86%-95.68M | -27.81%-98.06M | -41.06%-92.15M | -38.69%-332.13M | -68.82%-97.06M | -53.89%-93.02M | -17.03%-76.73M | -16.70%-65.33M | -28.42%-239.48M | 11.46%-57.49M |
| Income tax | 167K | -523K | -779K | -4.06M | -4.06M | 0 | 0 | 0 | 0 | |
| Net income | -3.04%-95.84M | -27.13%-97.54M | -39.87%-91.37M | -36.99%-328.07M | -61.75%-93M | -53.89%-93.02M | -17.03%-76.73M | -16.70%-65.33M | -28.42%-239.48M | 11.46%-57.49M |
| Net income continuous Operations | -3.04%-95.84M | -27.13%-97.54M | -39.87%-91.37M | -36.99%-328.07M | -61.75%-93M | -53.89%-93.02M | -17.03%-76.73M | -16.70%-65.33M | -28.42%-239.48M | 11.46%-57.49M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -3.04%-95.84M | -27.13%-97.54M | -39.87%-91.37M | -36.99%-328.07M | -61.75%-93M | -53.89%-93.02M | -17.03%-76.73M | -16.70%-65.33M | -28.42%-239.48M | 11.46%-57.49M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -3.04%-95.84M | -27.13%-97.54M | -39.87%-91.37M | -36.99%-328.07M | -61.75%-93M | -53.89%-93.02M | -17.03%-76.73M | -16.70%-65.33M | -28.42%-239.48M | 11.46%-57.49M |
| Basic earnings per share | 20.93%-0.34 | -5.26%-0.4 | -14.71%-0.39 | -16.18%-1.58 | -35.48%-0.42 | -22.86%-0.43 | 0.00%-0.38 | -3.03%-0.34 | 8.72%-1.36 | 18.42%-0.31 |
| Diluted earnings per share | 20.93%-0.34 | -5.26%-0.4 | -14.71%-0.39 | -16.18%-1.58 | -35.48%-0.42 | -22.86%-0.43 | 0.00%-0.38 | -3.03%-0.34 | 8.72%-1.36 | 18.42%-0.31 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
